Development of a Double Antibody Sandwich ELISA for West Nile Virus Detection Using Monoclonal Antibodies against Non-Structural Protein 1

Xi-Xia Ding¹, Xiao-Feng Li², Yong-Qiang Deng², Yong-Hui Guo³, Wei Hao¹, Xiao-Yan Che¹†, Cheng-Feng Qin²*, Ning Fu¹*

¹Laboratory of Emerging Infectious Diseases and Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, ²Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China

Abstract
The early diagnosis of West Nile virus (WNV) infection is important for successful clinical management and epidemiological control. The non-structural protein 1 (NS1) of flavivirus, a highly conserved and secreted glycoprotein, is abundant in the serum of flavivirus-infected patients and represents a useful early diagnostic marker. We developed a WNV-specific NS1 antigen-capture ELISA using two mouse monoclonal antibodies (MAbs) that recognised distinct epitopes of the NS1 protein of WNV as capture and detection antibodies. The antigen-capture ELISA displayed exclusive specificity to WNV without cross-reaction with other related members of the flavivirus family, including the dengue virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. Additionally, the specificity was presented as no false positive in normal (0/1003) and DENV-infected (0/107) human serum specimens. The detection limit of the antigen-capture ELISA was as low as 15 pg/ml of recombinant WNV NS1 protein (WNV-NS1) and 6.1 plaque-forming units (PFU)/0.1 ml of WNV-infected culture supernatant. In mice infected with WNV, the NS1 protein was readily detected in serum as early as one day after WNV infection, prior to the development of clinical signs of the disease. The sensitivity of the NS1 capture ELISA (93.7%) was significantly higher (79.4%) than that of real-time reverse transcription polymerase chain reaction in 63 serum samples from WNV-infected mice (p = 0.035). This newly developed NS1 antigen-capture ELISA with high sensitivity and specificity could be used as an efficient method for the early diagnosis of WNV infection in animals or humans.

Citation: Ding X-X, Li X-F, Deng Y-Q, Guo Y-H, Hao W, et al. (2014) Development of a Double Antibody Sandwich ELISA for West Nile Virus Detection Using Monoclonal Antibodies against Non-Structural Protein 1. PLoS ONE 9(10): e108623. doi:10.1371/journal.pone.0108623

Introduction
West Nile virus (WNV), a member of the flavivirus family, is closely related to significant pathogens such as yellow fever virus (YFV), dengue virus (DENV) type 1 to 4, Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), St. Louis encephalitis virus (SLEV), and Murray Valley encephalitis virus (MVEV). WNV is transmitted through a mosquito-bird-mosquito route and causes a range of illnesses in humans including mild fever, acute flaccid paralysis, and lethal encephalitis. WNV presents a global threat to human and animal health across the United States and Canada as well as in temperate regions such as Europe and Africa [1]. The public health concern regarding these diseases attracted increasing attention during the last decade in WNV endemic areas of Europe and the Middle East [2]. Since 1999, WNV has spread rapidly throughout North America, causing epidemics of WNV encephalitis, meningitis, and acute flaccid paralysis in naïve populations. There were 39,462 cases of WNV infection in the United States from 1999 to 2013, and 1663 deaths have been reported (http://www.cdc.gov/ncidod/dvbid/westnile/index.htm).

A specific therapy or vaccine has not been approved for WNV infection in humans, although passive transfer of specific antibodies and immunoglobulins has been used as a therapeutic attempt [3,4,5], and, therefore, an early, specific, and accurate diagnosis of WNV infection might be more important, particularly in regions where multiple flaviviruses co-circulate. The current diagnostic methods for WNV infection include serological tests, viral isolation, virus nucleic acid and infected cell detection. Generally, serological tests and virus nucleic acid detection by RT-PCR are used. RT-PCR requires specialised laboratory equipment and experienced technicians and could result in a false negative because of the short duration of viraemia and low virus titres during human WNV infection [6,7,8]. Serological tests, including detection of an antibody and virus protein, are considered specific and convenient, however, there are problems to be resolved. The
currently available commercial kits based on IgM antibody detection could be used to identify WNV infection. However, because of the 3–4 day window phase, the kits might be limited for early diagnosis as a result of the delay between initial infection and seroconversion [9,10]. Cross-reactivity with other flavivirus antibodies, prior exposure to heterologous flavivirus or vaccinations could interfere with and limit the usefulness of serological diagnostic tests [11]. Therefore, a method for the specific detection of viral antigens for early diagnosis of acute WNV infection is necessary.

The following two commercial immunochromatographic antigen test kits have recently become available for WNV detection in birds; the VecTest WNV antigen assay (Medical Analysis Systems, Inc., Camarillo, CA, USA) [12,13,14,15] and the Rapid Analyte Measurement Platform (RAMP) WNV test (Response Biomedical Corp., Burnaby, BC, Canada) [12,16]. These commercial tests have been used for rapid WNV antigen detection in mosquito emulsions, oral and cloacal swabs, and feathers obtained from dead crows with high viral copies [14,16]. The sensitivities of these two assay systems are only 10^5.17 PFU/ml and 10^3.17 PFU/ml for viral culture supernatants or 94% and 65% for WNV-positive mosquito pools [12], suggesting that the kits are less useful for screening for WNV infection because of their low sensitivities [14,16]. Based on the presence of NS1 in the acute-phase sera of DENV and WNV-infected patients and hamsters [17,19], more attention has been focused on the development of antigen-capture assays for the detection of the NS1 protein of flavivirus. NS1 is a highly conserved glycoprotein that is secreted at high levels and is detected in the serum of flavivirus-infected patients. In dengue-infected patients, the NS1 antigen was found circulating from the first day after the onset of fever up to day 9 after the onset of symptoms [19]. The NS1 antigen-capture assay used in WNV-infected hamsters and mice appears to enable early detection of infection even prior to the appearance of IgM [18,20]. The detection limit of these two assays are more than 0.5 ng/ml, and the assays appear not to be sensitive enough to enable detection at 3 days after infection, implying that these assays might not be useful for early diagnosis in clinical applications. In addition, the NS1 capture ELISA reported by Macdonald [10] is unable to distinguish between WNV and other flavivirus infections because the antibody used in this assay is directed against cross-reactive antigenic determinants shared by WNV and other flaviviruses. Saxena et al. used a WNV-NS1 polyclonal antibody as the capture antibody, and the inherent batch-to-batch variation ensures that this assay is not amenable to standardisation [21]. To establish the WNV-specific NS1 antigen-capture ELISA assay, we prepared a panel of MAbs and developed a highly sensitive and specific antigen-capture ELISA using two WNV-NS1 MAbs that recognise different epitopes of NS1 as capture and detection antibodies for the early diagnosis of WNV infection.

**Materials and Methods**

**Viruses and strains**

WNV strain Chin-01 (GenBank accession no. AJ490240.2) [22], JEV vaccine strain SA14-14-2 (GenBank accession no. D90195) [23,24], and TBEV strain An1 were from the Beijing Institute of Microbiology and Epidemiology in China. The four DENV serotype strains (DENV1, Hawaii; DENV2, New Guinea-C; DENV3, Guanxi-80-2; and DENV4, H241) and YFV strain 17D were obtained from the Guangzhou Center for Disease Control and Prevention, Guangzhou, China (Guangzhou CDC) [25,26,27]. Slides coated with immobilised WNV-infected cells were used to detect anti-WNV antibodies by an indirect immunofluorescence test (Euroimmun AG, Germany).

**Viral amplification**

The cell culture media and supplements were obtained from Invitrogen (Carlsbad, CA, USA). The WNV, JEV, TBEV, and YFV viruses were propagated in BHK21 cells in HEPES-buffered Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 50 µg/ml gentamicin and 2% foetal bovine serum and incubated at 37°C in a 5% CO2 atmosphere for 3–5 days. The four DENV serotype strains were propagated in C6/36 cells in Eagle’s Minimal Essential Media (MEM) supplemented with 50 µg/ml gentamicin and 2% foetal bovine serum and incubated at 33°C for 3–5 days. After the cytopathic effects were observed, the cell culture supernatants were collected and clarified by centrifugation at 1,500 rpm for 10 min. The titre of each virus pool was determined by a plaque assay in Vero-E6 cells, as previously reported [28].

**Serum samples**

The WNV-infected mouse models were performed as previously described [22]. Twenty-four-week-old specific-pathogen-free female BALB/c mice were infected intraperitoneally with a 1×10^6 PFU dose of WNV or JEV or mock infected with phosphate-buffered saline (PBS). The blood samples were collected daily for 24 hr by phlebotomy of the mouse tail veins, centrifuged at 3,000 rpm for 10 min, and frozen at −80°C until use. A total of 107 DENV1-infected patient sera samples were obtained from the Guangzhou CDC [29,30,31]. Control sera used for determining the cut-off value differentiating positive from negative samples were obtained from 1,003 healthy Chinese volunteers at Zhumadian Hospital of Southern Medical University, Guangzhou, China.

The experimental procedures involving animals were approved by and conducted in strict accordance with the guidelines of the Animal Experiment Committee of the State Key Laboratory of Pathogen and Biosecurity, Beijing, China. The patient serum samples [25,29,30] and control sera was obtained from blood donors, and the patient sera, with the following reference number: ZJYY-2012-JYYXB-002, was obtained from an existing collection approved by the Ethics Committee of the Zhumadian Hospital of Southern Medical University, Guangzhou, China.

**Preparation of recombinant NS1 protein**

The expression and purification of the rWNV-NS1 protein from *Escherichia coli* were performed as described previously [32]. The protein concentration was determined using a Bicinchoninic Acid Protein Assay Kit (Sigma-Aldrich, St. Louis, MO, USA), according to the manufacturer’s instructions. The rWNV-NS1 protein was identified by Western blot analysis using mouse anti-GST MAb and cross-reactive MAbs of flavivirus [32]. Additionally, the rNS1 proteins of the four DENV serotypes were prepared as described previously in our laboratory [25,26,27] and were used for the determination of the specificity and cross-reactivity of WNV-NS1 MAbs.

**Preparation and identification of MAbs against WNV-NS1**

The production and identification of MAbs against the NS1 protein were performed as described previously, with some modifications [27]. Briefly, 4- to 6-week-old female BALB/c mice were subcutaneously immunised with 50 µg of refolded rWNV-NS1 emulsified with complete Freund’s adjuvant (Sigma-Aldrich, USA), followed by three boosts with 30 µg of rWNV-NS1 in incomplete Freund’s adjuvant every 10 days by intraperitoneal
inoculation. Seven days after the fourth immunisation, the mice were bled, and the serum samples were collected and tested by ELISA with rWNV-NS1 as the coating antigen to determine the antibody titre against rWNV-NS1. The mice that had the highest antibody titre were administered an additional intraperitoneal inoculation with 100 µg of rWNV-NS1 in PBS, and the splenocytes were fused with mouse myeloma cells (NS-1) 3 days later. The hybridoma cells were screened primarily by an indirect ELISA with rWNV-NS1, rGST, or four serotypes of rDENV-NS1 proteins as coating antigens. The supernant of the screened cells were further confirmed by an indirect immunofluorescence assay (IFA) using slides coated with immobilised WNV-infected cells. Then, the specificity and cross-reactivity of the antibodies were further evaluated by an indirect IFA that detected antibodies binding to C6/36 cells infected with four serotypes of DENV, JEV, and YFV. The positive hybridoma cells were cloned by limited dilution. The MAbs isotypes were determined using a commercially available mouse MAb isotyping kit (Zymed Laboratories, Carlsbad, CA, USA). The MAbs were purified from ascitic fluids by the caprylic acid-ammonium sulfate precipitation method and conjugated with horseradish peroxidase (HRP; Sigma-Aldrich, USA) using periodate oxidation.

**Competition ELISA**

The binding epitopes of the MAbs were analysed using a competition ELISA with rWNV-NS1 protein as the coating antigen. Microwell plates (Costar Corning, Inc., Corning, NY, USA) were coated with 100 µl/well of rWNV-NS1 at a concentration of 1 µg/ml. After blocking, non-HRP-conjugated MAbs at a concentration of 500 µg/ml was incubated with HRP-conjugated MAbs at a dilution of 1:500 at 37°C for 1 hr. After the plates were washed, colour reactions were developed using tetramethylbenzidine (TMB, KPL, Gaithersburg, VA, USA) with hydrogen peroxide (H₂O₂) as a substrate solution and stopped with 0.3 N sulphuric acid (100 µl/well); the absorbance was read at 450 nm in an ELISA plate reader (Bio-Tek, Winooski, VT, USA). The influenza virus NS1 protein MAb IVNS1-M6 [33] was used as an irrelevant control. The percentage of inhibition was calculated according to the following formula: [%\text{OD}_{50} - \text{OD}_{150}] \times 100\%$, where OD$_{50}$ is the optical density at a wavelength of 450 nm. If the inhibition were greater than 75\%, it was defined as competitive inhibition; if the inhibition were between 75\% and 25\%, it was defined as relative competition; and if the inhibition were <25\%, it was defined as non-competitive inhibition.

**Development of MAb-based WNV-NS1 antigen-capture ELISA**

To select the best combination of capture and detection MAbs for a NS1 antigen-capture ELISA, NS1 MAbs were paired according to their affinity to different epitopes of rWNV-NS1. The procedure was performed as described previously [25], with slight modifications. Microplates (Costar, Corning, NY, USA) were coated with 100 µl/well of each capture MAb at a concentration of 10 µg/ml at 4°C overnight. After blocking, a series of diluted inactivated virus-infected culture supernatants and uninfected controls were added to the wells in duplicate and incubated at 37°C for 1 hr. After the plates were washed, the HRP-labelled MAbs were added in a working concentration, and the plates were incubated at 37°C for 30 min. Then, the wells were washed with phosphate-buffered saline Twenn-20 (PBS-T), followed by the addition of TMB. The reaction was stopped by the addition of sulphuric acid (0.5 N, 100 µl/well) 10 min later, and the absorbance was measured as described above.

**Detection of NS1 antigen in viral culture supernatants and sera using the NS1 antigen-capture ELISA**

To evaluate the sensitivity and specificity of the antigen-capture assay, a series of diluted rWNV-NS1 and rDENV-NS1 proteins starting from a concentration of 500 ng/ml to 1.9 pg/ml were analysed. Bovine serum albumin (BSA) was used to establish the baseline for the assay, and a sample was considered positive if the OD$_{150}$ was two fold greater than that of BSA. The inactivated viral culture supernatants of WNV, JEV, TBEV, YFV, four serotypes of DENV, and an uninfected culture supernatant as the control quantified by a plaque assay were used to evaluate the efficiency of the NS1 antigen-capture ELISA. Because WNV clinical samples are not available in China, samples from WNV-infected mice were subjected to the NS1 antigen-capture ELISA. The groups of BALB/c mice were administered with 1 x 10⁵ PFU of WNV, and sera were collected on days 1, 2, 3, 5, 6, and 7 post inoculation. Mice infected with JEV or mock infected with PBS were set as the controls. All the infected animal sera were serially diluted 100-fold in PBS, and the normal human sera were serially diluted 10-fold in PBS. The procedures for the NS1 antigen-capture ELISA were as described above. The cut-off value was set as the average value of the control sera plus five times the standard deviation (SD), and a sample was considered positive if it yielded an OD$_{150}$ value above the cut-off value. The end point dilutions of the detectable NS1 in the viral culture supernatants were defined as the highest dilution that showed an OD$_{150}$ value two fold greater than that of the uninfected culture supernatants.

**Real-time RT-PCR assay**

For the quantitation of viral RNA in the WNV-infected mouse serum samples, the viral RNA was harvested from 20 µl of serum using a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA). The average number of WNV RNA copies in each sample was determined from 5 µl of extract in duplicate by a real-time RT-PCR assay using a Taqman fast virus one-step Master Mix kit (Life Technologies, Foster City, CA, USA) and fluorescent primer probe sets for the WNV E gene [34].

**Statistical Analysis**

The data were analysed with Prism software (GraphPad Software). The statistical data were calculated using SPSS statistical package version 20. The chi-squared test was used to evaluate the statistical significance of the results between the WNV-NS1 ELISA and the real-time RT-PCR assay. A P value of <0.05 was considered statistically significant for all the parameters.

**Results**

**Selection and characterisation of capture and detection MAbs for WNV-NS1 antigen-capture ELISA**

A total of 65 hybridoma cell clones that produced MAbs against WNV-NS1 protein were established based on their strong positive reactivity with the rWNV-NS1 protein in the ELISA and the WNV-infected cells in the IFA. The specificity of the MAbs was further identified by excluding their cross-reactivity to the four serotypes of DENV, JEV, and YFV using IFA and the four serotypes of DENV-NS1 protein using ELISA. The IgG isotype determination revealed that the 65 MAbs consisted of IgG1 (n = 46), IgG2a (n = 8), IgG2b (n = 9), and IgG3 (n = 2). The characteristics of these MAbs are shown in **Table 1**. Of the 65 MAbs, named WNVSNS1-M1 to WNVSNS1-M65, 39 MAbs specifically reacted with WNV-NS1 without cross-reactivity with
Table 1. Characteristics of MAbs against the NS1 protein of WNV.

| Hybridoma (original clone no.) | Isotype | Epitope group | ELISA result\(^a\): | IFA result\(^b\): |
|--------------------------------|---------|---------------|---------------------|------------------|
|                                |         |               | WNV | DENV1 | DENV2 | DENV3 | DENV4 | WNV | DENV1 | DENV2 | DENV3 | DENV4 | JEV | YFV |
| WNVNS1-M1                      | IgG1    | I             | +++ | -     | -     | -     | -     | ++  | -     | -     | -     | -     | -    | -   |
| WNVNS1-M2                      | IgG1    | XIII          | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M3                      | IgG1    | II            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M4                      | IgG1    | III           | +++ | -     | -     | -     | -     | ++   | -     | -     | -     | -     | -    | -   |
| WNVNS1-M5                      | IgG1    | II            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M6                      | IgG1    | II            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M7                      | IgG2    | IV            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M8                      | IgG1    | VIII          | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M9                      | IgG1    | III           | ++  | -     | -     | -     | -     | ++   | -     | -     | -     | -     | -    | -   |
| WNVNS1-M10                     | IgG1    | IV            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M11                     | IgG1    | V             | +++ | -     | -     | -     | -     | ++   | -     | -     | -     | -     | -    | -   |
| WNVNS1-M12                     | IgG2a   | VII           | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M13                     | IgG1    | X             | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M14                     | IgG3    | VI            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M15                     | IgG2b   | IV            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M16                     | IgG2b   | VII           | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M17                     | IgG1    | IX            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M18                     | IgG1    | IV            | +++ | -     | -     | -     | -     | ++   | -     | -     | -     | -     | -    | -   |
| WNVNS1-M19                     | IgG1    | XII           | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M20                     | IgG1    | IV            | +++ | -     | -     | -     | -     | ++   | -    | -     | -     | -     | -    | -   |
| WNVNS1-M21                     | IgG1    | IV            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M22                     | IgG1    | IV            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M23                     | IgG1    | IV            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M24                     | IgG1    | XI            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M25                     | IgG1    | VI            | +++ | -     | -     | -     | -     | +    | -    | -     | -     | -     | -    | -   |
| WNVNS1-M26                     | IgG1    | III           | ++  | -     | -     | -     | -     | +++  | -    | -     | -     | -     | -    | -   |
| WNVNS1-M27                     | IgG1    | XII           | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M28                     | IgG1    | VII           | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M29                     | IgG2b   | VII           | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M30                     | IgG1    | VI            | +++ | -     | -     | -     | -     | ++   | -    | -     | -     | -     | -    | -   |
| WNVNS1-M31                     | IgG2a   | VII           | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M32                     | IgG1    | VI            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M33                     | IgG2b   | VII           | +++ | -     | -     | -     | -     | +    | -    | -     | -     | -     | -    | -   |
| WNVNS1-M34                     | IgG    | VII           | +++ | -     | -     | -     | +~+  | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M35                     | IgG2b   | VII           | +++ | -     | -     | -     | +~+  | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M36                     | IgG1    | VI            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M37                     | IgG1    | VI            | +++ | -     | -     | -     | +     | -    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M38                     | IgG1    | VII           | +++ | -     | -     | -     | -     | +    | -    | -     | -     | -     | -    | -   |
| WNVNS1-M39                     | IgG1    | V             | +++ | -     | -     | -     | -     | +    | -    | -     | -     | -     | -    | -   |
| WNVNS1-M40                     | IgG1    | ND\(^c\)      | +++ | -     | -     | -     | +++  | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M41                     | IgG2a   | ND            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M42                     | IgG2b   | ND            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M43                     | IgG1    | ND            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M44                     | IgG1    | ND            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M45                     | IgG1    | ND            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | -   |
| WNVNS1-M46                     | IgG2a   | ND            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | +   |
| WNVNS1-M47                     | IgG2a   | ND            | +++ | -     | -     | -     | -     | +    | -     | -     | -     | -     | -    | ++  |
the four serotypes of DENV, JEV, and YFV in either ELISA or IFA, indicating that the 39 MAbs specific for WNV could be useful for developing a WNV-NS1-specific antigen-capture ELISA. The remaining 26 MAbs exhibited cross-reactivity with the four serotypes of DENV and JEV in different cross-reactive patterns. The sensitivity of the sandwich formation requires a pair of

| Hybridoma (original clone no.) | Isotype | Epitope group | ELISA resulta: | IFA resultb: |
|--------------------------------|---------|---------------|----------------|---------------|
|                                |         |               | WNV  | DENV1 | DENV2 | DENV3 | DENV4 | WNV  | DENV1 | DENV2 | DENV3 | DENV4 | JEV | YFV |
| WNVNS1-M48 IgG2b              | ND      |               | +++  | -     | +++  | -     | -     | -     | +++  | -     | -     | -     | -    | +++ |
| WNVNS1-M49 IgG1               | ND      |               | +++  | -     | -    | -     | -     | -     | +++  | +     | +     | +     | +    | -   |
| WNVNS1-M50 IgG1               | ND      |               | +++  | +++   | +++  | +++   | +++   | +++   | +     | +     | +     | +     | +    | +   |
| WNVNS1-M51 IgG1               | ND      |               | +++  | +++   | -    | -     | -     | -     | -     | +     | +     | -     | -    | ++  |
| WNVNS1-M52 IgG2a              | ND      |               | +++  | -     | +++  | -     | -     | -     | +++  | -     | -     | -     | -    | +   |
| WNVNS1-M53 IgG2b              | ND      |               | +++  | -     | +++  | +     | -     | -     | +++   | -     | -     | -     | -    | +   |
| WNVNS1-M54 IgG2a              | ND      |               | ++++ | +++   | +++  | +++   | +++   | +++   | +     | -     | -     | -     | -    | +   |
| WNVNS1-M55 IgG1               | ND      |               | +++  | -     | -    | -     | -     | -     | +     | -     | -     | -     | -    | +   |
| WNVNS1-M56 IgG2a              | ND      |               | +++  | -     | -    | +     | +     | +     | +     | -     | -     | -     | -    | +   |
| WNVNS1-M57 IgG1               | ND      |               | +++  | -     | +++  | -     | -     | -     | +++   | -     | -     | -     | -    | +   |
| WNVNS1-M58 IgG1               | ND      |               | +++  | -     | +++  | +++   | -     | -     | -     | -     | -     | -     | -    | +++ |
| WNVNS1-M59 IgG1               | ND      |               | ++++ | -     | -    | -     | -     | -     | +++   | -     | -     | -     | -    | ++  |
| WNVNS1-M60 IgG1               | ND      |               | ++++ | -     | -    | -     | -     | -     | +++   | -     | -     | -     | -    | ++  |
| WNVNS1-M61 IgG2b              | ND      |               | +++  | -     | -    | -     | -     | -     | +     | -     | -     | -     | -    | +   |
| WNVNS1-M62 IgG1               | ND      |               | +++  | -     | -    | -     | -     | -     | +     | -     | -     | -     | -    | +   |
| WNVNS1-M63 IgG1               | ND      |               | +++  | -     | -    | -     | -     | -     | +     | -     | -     | -     | -    | +   |
| WNVNS1-M64 IgG1               | ND      |               | ++++ | -     | -    | -     | -     | -     | -     | -     | -     | -     | -    | +   |
| WNVNS1-M65 IgG1               | ND      |               | ++++ | -     | -    | -     | -     | -     | -     | -     | -     | -     | -    | +   |

*aPurified recombinant WNV-NS1 protein and DENV-NS1 were used as the coating antigen and were reacted with purified MAbs against the NS1 protein. The absorbance was measured at 450 nm: +, OD_{450} = 0.5 to 1; ++, OD_{450} = 1 to 2; ++++, OD_{450} = 2 to 3; OD_{450} > 3.

*bThe reactivity of each MAb was determined by IFA with WNV, DENVs, YFV, and JEV, and their IFA reactivity with normal cells were negative (data not shown). –, no reactivity; +, weak reactivity; ++, intermediate reactivity; ++++, strong reactivity.

*Not detected.

doi:10.1371/journal.pone.0108623.t001

The sensitivity of the double antibody sandwich ELISA using different capture and detection MAbs pairs. The detection of NS1 in culture supernatants of WNV-infected cells by different MAb pairs. The culture supernatants of WNV-infected cells were serially diluted 2-fold. Data points represent the mean ± standard deviation from three replicates. The most effective pairs were determined by the highest dilution of the OD_{450} values.

doi:10.1371/journal.pone.0108623.g001
antibodies that are capable of binding to discrete, non-overlapping epitopes of the antigen [35]. Thus, the epitopes recognised by these MAbs were determined by a competition ELISA with rWNV-NS1 as the coating antigen. The 39 anti-rWNV-NS1 MAbs were divided into at least 13 groups, and each group reacted with the identical epitope or sterically overlapped the rWNV-NS1 epitopes. All of the 39 MAbs specific to WNV-NS1 were paired according to their abilities to recognise distinct epitopes of NS1. The eight most effective pairs of capture and detection MAbs that recognised different epitopes were primarily selected based on their sensitivity to detect the WNV-NS1 protein (Fig. 1). The MAb pair of immobilised M6 and HRP-M4 was demonstrated to be the most effective to detect WNV among the eight pairs of MAbs. A checkerboard analysis of the serial dilutions of the capture and detection antibodies was conducted to optimise the reaction conditions of the antigen-capture assay. The optimal concentration for the capture by MAb M6 was determined as 10 μg/ml and for detection by MAb HPR-M4 was 1:1000.

Figure 2. Evaluation of the sensitivity and specificity of the rWNV-NS1 antigen-capture ELISA. A, The NS1 standard curve as determined by the purified rWNV-NS1 antigen-capture ELISA. Various concentrations of WNV-NS1 and DENV1-4-NS1 proteins were analysed. BSA was used to establish the baseline. B, The detection of NS1 in WNV-infected cell culture supernatants and other closely related members of the flavivirus family, DENV, JEV, YFV, and TBEV, by the NS1 antigen-capture ELISA. Two-fold serially diluted supernatants from WNV-, four DENV serotype-, JEV-, YFV-, or TBEV-infected cells were subjected to the WNV-NS1 antigen-capture ELISA. Data points represent the mean ± standard deviation from three replicates. The cut-off value was set at twice the average value of the negative controls from three replicates. Positive OD450 values were only observed for the WNV-NS1 protein and WNV-infected cell supernatants.

doi:10.1371/journal.pone.0108623.g002

Figure 3. The detection of NS1 in WNV-infected mice sera by the NS1 antigen-capture ELISA. The data represent the OD450 of the serum samples at 1:100 dilution. The dashed line represents the cut-off value, which is twice the mean value of the negative control. Each data point represents the mean OD450 of duplicate assays. The results were considered positive if a sample yielded an OD450 above the cut-off value. The cut-off value was set as twice the mean value of the negative control. Each data point represents the mean OD450 of duplicate assays.

doi:10.1371/journal.pone.0108623.g003
Specificity and sensitivity of the WNV-NS1 antigen-capture ELISA

To evaluate the detection limit and specificity of the antigen-capture ELISA, the 2-fold serially diluted rWNV-NS1 and rDENV-NS1 proteins were tested in duplicate. BSA was used to establish the baseline. The detection limit of the rWNV-NS1 protein was approximately 15–30 pg/ml, and the linear portion of the standard curve ranged from 15.62 to 125 ng/ml (Fig. 2A). There was no positive result with the rDENV-NS1 protein. The specificity and sensitivity of the WNV-NS1 capture ELISA was further assessed by testing for the presence of NS1 in the culture supernatants of WNV, four serotypes of DENV, JEV, YFV, and TBEV (Fig. 2B). Only the WNV-infected cell culture supernatants presented a positive signal. The sensitivity of the assay was approximately 6.1 PFU/0.1 ml for the WNV-infected supernatants, and no positive results or cross-reactivity were observed for the four serotypes of DENV, JEV, YFV, or TBEV. These results indicate that the NS1 antigen-capture assay is specific for the detection of WNV.

Validation with clinical samples

Using this assay, the soluble NS1 was reliably detected starting from day 1 after the WNV infection in mice, with peak NS1 concentration at day 4, whereas the NS1 protein began to decrease on day 6 (Fig. 3). On days 1 and 3 after infection, NS1 was detected in 85.7% (12/14) and 100% (11/11) of the serum samples among the WNV-infected mice and was not detected in the JEV-infected and mock PBS-infected mice. Additionally, the sensitivity of the WNV-NS1 capture ELISA was compared to the real-time RT-PCR assay in 63 serum samples from 14 WNV-infected mice (See Table 2). The WNV-NS1 capture ELISA displayed a markedly greater sensitivity with the WNV-infected mice sera, and variations in sensitivity between the antigen-capture ELISA and the real-time RT-PCR were statistically significant as revealed by chi-squared tests ($P = 0.035$).

To establish the baseline of the WNV-NS1 antigen-capture assay for the clinical evaluation, the control sera from 1003 healthy Chinese volunteers were analysed. The mean OD$_{450}$ value of these sera was 0.01, with a SD of 0.0031. Next, the cut-off value was set as follows: 0.01 + 0.0031 x 5 = 0.0255. By these criteria, none of the 1003 sera samples from healthy blood donors was defined as positive. Thus, the detection of the WNV-NS1 protein had a specificity of 100% (1003 of 1003).

A total of 107 serum specimens collected from patients during the DENV-1 epidemic in Guangdong in 2006, which were confirmed as DENV1-NS1 antigen-positive by our previous study [25], were examined using this assay. All of the specimens were negative in this assay, indicating the specificity of the WNV-NS1 antigen-capture ELISA.

Discussion

Because of the cross-reactivity of anti-flavivirus antibodies, prior exposure to heterologous flavivirus or vaccinations could limit the utility of serological diagnostic tests [11]. However, there has been no effective commercial antigen detection kit for WNV infection in humans. Macdonald and Saxena have developed two NS1 antigen-capture ELISAs, however, these assays do not effectively distinguish WNV from other flavivirus infections or standardization because the antibodies used in these assays are either a flavivirus NS1 protein cross-reactive MAb or a WNV-NS1 polyclonal antibody. These results in poor specificity in detecting WNV or intra- and inter-laboratory variability caused by batch-to-batch variations in polyclonal antisera. Compared to a polyclonal antibody, the advantages of a MAb-based assay are stability and specificity for diagnosis and research because MAbs from stable hybridoma clones could ensure a continuous supply of large quantities of well characterised antibodies against unique epitopes. The assay system in our work is based on two MAbs recognising different epitopes of the WNV-NS1 protein.

In this study, 65 MAbs against WNV-NS1 were produced by immunising mice with rWNV-NS1. The reaction profile of each antibody was characterised by indirect ELISA and IFA. A total of 26 of 65 MAbs showed cross-reactivity with the four serotypes of DENV and JEV in different cross-reactive patterns, whereas the other 39 MAbs were found to be specific to WNV-NS1 only. These MAbs specifically recognised at least 13 different epitopes of the NS1 protein of WNV, allowing the selection of an optimal pair of MAbs for constructing a double antibody sandwich ELISA. The matched pair of Mab M6 as the capture antibody and Mab M4 as the detection antibody exhibited specific binding to the WNV-infected culture supernatant with a detection limit as low as 6.1 PFU/0.1 ml, without cross-reactivity with the other closely related members of the flavivirus family such as DENV, JEV, YFV, and TBEV. The detection limit of the antigen-capture ELISA was as low as 15 pg/ml, which was much more sensitive than that of 5 ng/ml in the WNV-NS1 ELISA reported by Saxena [21] and 0.5 ng/ml reported by Chung KM [20]. By our assay
system, WNV-NS1 sera could be detected at day 1 after infection, compared with day 3 [20]. This high sensitivity and specificity of our ELISA system might be attributed to the sandwich construction paired with the two MAbs selected from 39. We hypothesise that a polyclonal capture antibody might not have high enough affinity to target the predominant epitopes of NS1 because of steric effects, thus decreasing the sensitivity of the assay. In addition, an antigen assay based on polyclonal antibodies is subject to intra- and inter-laboratory variability caused by batch-to-batch variations resulting from the use of antisera from different animals, which might be unfavourable to the stability of a detection system and development of a commercial kit. MAbs from stable hybridoma clones ensure a continuous supply of large quantities of well-characterised antibodies that could be easily standardised among different laboratories, which could be developed into a commercial kit in the future. With its high sensitivity in detecting WNV-NS1, the NS1 antigen-capture ELISA might diagnose WNV infection caused by a low viraemia level. This NS1 antigen-capture ELISA was able to detect the WNV antigen of sera in infected mice as early as one day after WNV infection. The detectable NS1 antigen concentration peaked at day 4 and then declined from day 6. The decrease of detectable NS1 in mice sera is likely caused by the production of a specific anti-NS1 antibody, which forms an antibody-antigen complex, thus diminishing the levels of free NS1 and reducing the consequent sensitivity of the antigen-capture ELISA. This finding is in accordance with a previous study in which dissociated NS1 immune complexes extend the window of detection [20]. The positive detection rates of WNV-NS1 increased from 85.7% at 1–4 days to 100% at 5–7 days post infection among the WNV-infected mouse serum samples, whereas the serum samples from the JEV-infected and PBS-treated mice were negative. Additionally, the NS1 antigen-capture ELISA displayed greater sensitivity than that of real-time RT-PCR from 1 to 7 days in WNV-infected mouse serum samples (P = 0.035), which might be attributed to the short duration of viraemia and low viral RNA titres after WNV infection [6,7,8]. For this reason, RT-PCR could not successfully detect WNV-infected sera during the whole process of murine infection, whereas the antigen-capture ELISA could do so.

Our antigen-capture ELISA did not cross-react with the supernatants of four serotypes of DENV, JEV, YFV, or TBEV-infected cell cultures and the sera of DENV1-infected patient. This WNV-NS1 antigen-capture ELISA shows a sensitivity of 6.1 PFU/0.1 ml in culture supernatants and 15 pg/ml for the WNV-NS1 protein as well as a specificity of 100% for the virus culture supernatants and serum samples, which resulted in early detection on day 1 after the infection of mice. Because there is no WNV-infected human serum specimen in China, we made the mock WNV-infected human serum specimens by adding WNV that had been quantified by plaque assay into normal human serum specimens and 37°C incubation for 1 hr, with 2-fold serial dilutions of the serum samples for the analysis. This antigen-capture ELISA measured the mock WNV-infected human serum with a limit of detection of 48.8 PFU/0.1 ml, which was approximately 8 fold lower than that of the WNV-infected culture supernatant. This finding might be attributed to the differential substrate environments of the serum and culture supernatants or some of the NS1 epitopes might have been blocked by the immunoglobulins of the human serum. It could be possible that our NS1-capture ELISA system with high specificity and sensitivity would provide an efficient tool for the detection of WNV infections with early diagnosis, particularly in some regions, such as Asia and North America where there is a high incidence of WNV infection and the population is vaccinated against other flaviviruses (JEV, YFV, and TBEV), rendering serological tests difficult to interpret [36]. Hu et al. proposed that an accurate diagnosis of an acute DENV infection requires a combination of several tests performed at different stages of the disease [31]. It is necessary to combine our NS1-capture ELISA and the IgM antibody test to enhance diagnostic effectiveness, which would be expected to be further evaluated with WNV-infected clinical serum samples in the future.

Acknowledgments

We thank the Guangzhou Center for Disease Control and Prevention, Guangzhou, China for providing the DENV1-infected patient sera samples.

Author Contributions

Conceived and designed the experiments: XXD NF XYC CFQ. Performed the experiments: XXD XFL. Analyzed the data: XXD NF XYC CFQ. Contributed reagents/materials/analysis tools: YQD YHG. Performed the experiments: XXD XFL. Analyzed the data: XXD NF XYC CFQ. Conceived and designed the experiments: XXD NF XYC CFQ. Contributed reagents/materials/analysis tools: YQD YHG. Wrote the paper: XXD NF XYC CFQ.

References

1. Hayes EB, Komar N, Nasci RS, Montgomery SP, O’Leary DR, et al. (2005) Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 11: 1167–1173.
2. Zeller HG, Schaffner WE (2004) West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis 23: 147–156.
3. Julander JG, Winger QA, Olsen AL, Day CW, Sidwell RW, et al. (2005) Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fatal titers and increases dam survival. Antiviral Res 65: 79–85.
4. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522–530.
5. Ben-Nathan D, Lustig S, Tam G, Robinson S, Segal S, et al. (2003) Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 188: 5–12.
6. Busch MP, Caggioti S, Robertson EF, McAuley JD, Tobler LH, et al. (2005) Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 353: 460–467.
7. Busch MP, Tobler LH, Saldanha J, Caggioti S, Shyamala V, et al. (2005) Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. Transfusion 45: 492–499.
8. Castillo-Olivares J, Wood J (2004) West Nile virus infection of horses. Vet Res 35: 467–483.
9. Ratterree MS, Gutierrez RA, Travassos DR, Dille BJ, Beasley DW, et al. (2004) Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis 189: 669–676.
10. Tardei G, Ruta S, Chiu V, Rossi C, Tsai TF, et al. (2000) Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. J Clin Microbiol 38: 2232–2239.
11. Kini Y, Kondo T, Konishi E (2011) Non-structural protein 1 (NS1) antibody-based assays to differentiate West Nile (WN) virus from Japanese encephalitis virus infections in horses: effects of WN virus NS1 antibodies induced by inactivated WN vaccine. J Virol Methods 171: 123–128.
12. Burkhalter KL, Lindsay R, Anderson R, Dibernardo A, Fong W, et al. (2006) Evaluation of commercial assays for detecting West Nile virus antigen. J Am Mosq Control Assoc 22: 64–69.
13. Suri S, Sargent C, Langer RC, Parsons R, Vanlandingham DL, et al. (2004) Comparative sensitivity of the VecTest antigen-capture assay, reverse transcriptase-PCR, and cell culture for detection of West Nile virus in dead birds. Vector Borne Zoonotic Dis 4: 204–209.
14. Shope RB, Okoniewski MJ, Therrien JE, Kramer LD, Kauffman EB, et al. (2004) VecTest as diagnostic and surveillance tool for West Nile virus in dead birds. Emerg Infect Dis 10: 2175–2181.
15. Lindsay R, Barker I, Nayar G, Drebot M, Calvin S, et al. (2003) Rapid antigen-capture assay to detect West Nile virus in dead corvids. Emerg Infect Dis 9: 1406–1410.
16. Padgett KA, Cahoon-Young B, Carney R, Woods L, Read D, et al. (2006) Field and laboratory evaluation of diagnostic assays for detecting West Nile virus in...
oropharyngeal swabs from California wild birds. Vector Borne Zoonotic Dis 6: 183–191.

17. Young PR, Hilditch PA, Bletchly C, Halloran W (2000) An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol 38: 1053–1057.

18. Macdonald J, Tomy J, Hall RA, Williams B, Palacios G, et al. (2005) NS1 protein secretion during the acute phase of West Nile virus infection. J Virol 79: 13924–13933.

19. Akon S, Tallarmin A, Debruyne M, Falconar A, Deubel V, et al. (2002) Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol 40: 576–581.

20. Chung KM, Diamond MS (2008) Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice. J Med Virol 80: 547–556.

21. Saxena D, Kumar JS, Parida M, Sivakumar RR, Patro IK (2013) Development and evaluation of NS1 specific monoclonal antibody based antigen capture ELISA and its implications in clinical diagnosis of West Nile virus infection. J Clin Virol 58: 529–534.

22. Li XF, Jiang T, Yu XD, Deng YQ, Zhao H, et al. (2010) RNA elements within the 5′ untranslated region of the West Nile virus genome are critical for RNA synthesis and virus replication. J Gen Virol 91: 1218–1223.

23. Li SH, Li XF, Zhao H, Deng YQ, Yu XD, et al. (2013) Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2. Virol J 10: 64.

24. Li SH, Dong H, Li XF, Xie X, Zhao H, et al. (2013) Rational design of a flavivirus vaccine by abolishing viral RNA 2′-O methylolation. J Virol 87: 5012–5019.

25. Ding X, Hu D, Chen Y, Di B, Jin J, et al. (2011) Full serotype- and group-specific NS1 capture enzyme-linked immunosorbent assay for rapid differential diagnosis of dengue virus infection. Clin Vaccine Immunol 18: 430–434.

26. Xu H, Di B, Pan YX, Qiu LW, Wang YD, et al. (2006) Serotype 1-specific monoclonal antibody-based antigen capture immunoassay for detection of circulating nonstructural protein NS1: Implications for early diagnosis and serotyping of dengue virus infections. J Clin Microbiol 44: 2872–2878.

27. Qiu LW, Di B, Wen K, Wang XS, Liang WH, et al. (2009) Development of an antigen capture immunoassay based on monoclonal antibodies specific for dengue virus serotype 2 nonstructural protein 1 for early and rapid identification of dengue virus serotype 2 infections. Clin Vaccine Immunol 16: 88–95.

28. Rohrig JT, Hombach J, Barrett AD (2008) Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. Viral Immunol 21: 123–132.

29. Zheng K, Zhou HQ, Yan J, Ke CW, Maeda A, et al. (2009) Molecular characterization of the E gene of dengue virus type 1 isolated in Guangdong province, China, in 2006. Epidemiol Infect 137: 73–78.

30. Bai Z, Liu L, Tu Z, Yao L, Liu J, et al. (2008) Real-time PCR for detecting circulating dengue virus in the Guangdong Province of China in 2006. J Med Microbiol 57: 1347–1352.

31. Hu D, Di B, Deng X, Wang Y, Chen Y, et al. (2011) Kinetics of non-structural protein 1, IgM and IgG antibodies in dengue type 1 primary infection. Virol J 8: 47.

32. Yong-hui G, Kun W, Yu-xian P, Li-wen Q, Xiu-xia D, et al. (2009) Cloning and expression of the NS1 gene encoding the non-structural protein I of West Nile Virus and the analysis of its antigenicity. CHINESE JOURNAL OF ZOOONSES 25: 545–548.

33. DING X, Hoi-wah T, QIU L, WANG Y, YUAN G, et al. (2010) Antigen capture ELISA for specific detection of influenza A virus NS1 protein. Chinese Journal of Microbiology and Immunology: 566–569.

34. Yong-qiang D, Tao J, Man YU, Cheng-Feng Q, Shui-Feng C, et al. (2005) Detection of West Nile virus using real-time PCR assay. CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY 25: 519–522.

35. Porstmann T, Kiessig ST (1992) Enzyme immunoassay techniques. An overview. J Immunol Methods 150: 5–21.

36. Mackenzie JS, Gubler DJ, Peterson LR (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S09–S109.